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Background:Mutations in the CACNA1A gene encoding the voltage-gated calcium channelα1A subunit have been
identiﬁed in patients with autosomal dominantly inherited neurological disorders, including spinocerebellar
ataxia type 6 (SCA6) and familial hemiplegic migraine type 1 (FHM1). In order to investigate the underlying
pathogenesis common to these distinct phenotypic disorders, this study investigated the neuronal function of
the GABAergic system and glucose metabolism in vivo using positron emission tomography (PET).
Methods: Combined PET studies with [11C]-ﬂumazenil and [18F]-ﬂuorodeoxyglucose (FDG) were performed in
three FHM1 patients and two SCA6 patients. [18F]-FDG-PET using a three-dimensional stereotactic surface
projection analysis was employed to measure the cerebral metabolic rate of glucose (CMRGlc). In addition, the
GABA-A receptor function was investigated using ﬂumazenil, a selective GABA-A receptor ligand.
Results: All patients displayed a signiﬁcant decrease in CMRGlc and low ﬂumazenil binding in the cerebellum
compared with the normal controls. The ﬂumazenil binding in the temporal cortex was also decreased in two
FHM1 patients.
Conclusions: Cerebellar glucose hypometabolism and an altered GABA-A receptor function are characteristic of
FHM1 and SCA6.
General signiﬁcance: An altered GABA-A receptor function has previously been reported in models of inherited
murine cerebellar ataxia caused by a mutation in the CACNA1A gene. This study showed novel clinical character-
istics of alteration in the GABA-A receptor in vivo, which may provide clinical evidence indicating a pathological
mechanism common to neurological disorders associated with CACNA1A gene mutation.© 2014 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/3.0/).1. Introduction
Neuronal Ca2+plays a role in various neuronal pathways for excitabil-
ity and neurotransmitter release and is regulated by calcium-permeable
channels and calcium binding proteins. Voltage-gated calcium chan-
nels (VGCCs) help to regulate neuronal Ca2+ and function as
heteromultimeric complexes that mediate calcium inﬂux into cells
in response to changes in the membrane potential. The α1A subunit,
encoded by the CACNA1A gene, is a pore-forming structure speciﬁc to
the brain speciﬁc P/Q-type VGCC, which is diffusedly expressed in
the brain, especially in the Purkinje cells of the cerebellum [1].
Mutations in the CACNA1A gene have been identiﬁed in autosomal
dominantly inherited human neurological disorders, includingicine, Hamamatsu University
-3192, Japan. Tel.: +81 53 435
. This is an open access article underspinocerebellar ataxia type 6 (SCA6), episodic ataxia 2 (EA2) and famil-
ial hemiplegic migraine type 1 (FHM1) [2]. SCA6 is caused by small ex-
pansions in the CAG repeat at the 3′ endof the CACNA1A gene,while EA2
and FHM1 are the result of point mutations in the CACNA1A gene. The
phenotypes of FHM1 exhibit remarkable variation, including episodic
neurological symptoms, such as seizures, transient blindness and per-
manent neurological symptoms of cerebellar ataxia [3,4]. Phenotypic
variation is also observed in patients with speciﬁc CACNA1A genemu-
tations and family members with a single mutation [4,5]. Cerebellar
ataxia is the most frequently observed phenotype in FHM1 patients,
and some FHM1 patients develop ataxia as the only neurological sign,
without migraines [3,6]. Therefore, cerebellar signs are clinically indis-
tinguishable in cases of FHM1 and SCA6.
Several inheritedmouse neurological disorders can be caused by the
CACNA1A gene. Mutations at the orthologous site of the mouse
CACNA1A gene induce a group of recessive neurological disorders, in-
cluding the tottering phenotypes with ataxia and absence epilepsy, as
well as the rolling Nagoya phenotype with ataxia without seizures [2].the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/3.0/).
Table 1
Characteristics of the patients with CACNA1Amutations.
Patient
No./sex/age
Phenotype
Ataxia
Age at onset (y)
Progression
SARA score Migraine
Age at onset (y)
Type of aura
CACNA1A gene
mutation
1/F/55
FHM1
35
Progressive
10 13
Motor
R1437Q/wt
2/M/31
FHM1
22
Progressive
9 9
Visual
R1437Q/wt
3/F/24
FHM1
20
Progressive
9 12
Motor & visual
R1437Q/wt
4/M/48
SCA6
30
Progressive
9 (–) (CAG)21/(CAG)10
5/F/54
SCA6
34
Progressive
10 (–) (CAG)21/(CAG)10
CACNA1A reference sequence: X99897.
SARA: scale for the assessment and rating of ataxia.
wt: wild-type.
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animal model of human spinocerebellar ataxia, and recent studies
of these animals have demonstrated an abnormal glutamic acid to
γ-aminobutyric acid (GABA)-A receptor function and expression in
the cerebellar and cerebral cortices resulting from an abnormal P/Q
type VGCC activity [7–10]. These ﬁndings led us to speculate that
the GABA-A receptor function may also be compromised in patients
with SCA6 and FHM1. This study therefore investigated the neuronal
function of the GABAergic system using positron emission tomography
(PET) with a radioligand, [11C]-ﬂumazenil, that binds selectively to
the GABA-A receptor and evaluated brain glucose metabolism
using [18F]-ﬂuorodeoxyglucose (FDG) in FHM1 and SCA6 patients.
We herein describe functional GABA-A receptor alterations in patients
with the CACNA1A gene mutation.
2. Patients and methods
2.1. Patients
After obtaining permission from the local ethics committee and
written informed consent according to the Declaration of Helsinki,
three FHM1patients (onemale and two females) and two SCA6 patients
(one male and one female) were included in this study.
Neurological specialists excluded other possible causes of cerebellar
ataxia, including infection, other autoimmune conditions, vitamin deﬁ-
ciencies, cerebrovascular diseases and neoplasms. FHM1was diagnosed
based on clinical criteria published by the International Classiﬁcation of
Headache Disorders [11]. The degree of cerebellar ataxia was evaluated
using a uniform clinical examinationwith a scale for the assessment and
rating of ataxia (SARA) [12]. All patients underwent brain magnetic
resonance imaging (MRI) after the initial presentation of symptoms.
2.2. Mutation analysis
Genomic DNA was extracted from the leukocytes of the subjects'
family members using a DNA Isolation kit (WAKO, JAPAN). Primers cor-
responding to the intronic sequences ﬂanking the exons of the CACNA1A
gene were designed using the Primer3 software program. Polymerase
chain reaction (PCR) was performed with the GoTaq system (Promega,
USA) under standard conditions. The PCR products were puriﬁed with
ExoSAP (USB, USA) and sequenced for both forward and reverse strands
using the BigDye Terminator chemistry version 3 kit according to the
standard protocol (Applied Biosystems, CA). Sequences were subse-
quently obtained using the ABI Genetic Analyzer 3100 (Applied
Biosystems) with the sequence analysis software program GENETYX,
ver. 9 (GENETYX, JAPAN).
2.3. PET imaging
The FDG-PET studies were performedwith the patient in a resting
state with his or her eyes open under a dim light following the intra-
venous injection of 185 MBq [18F]-FDG. All scans were realigned to
the anterior–posterior commissure line and spatially normalized to
the Talairach and Tournoux atlas using an afﬁne transformation
with 12 parameters, followed by nonlinear warping. This process
yielded a standardized image set with 2.25 mm voxels. The spatially
normalized FDG-PET scan for each subject was compared with a norma-
tive reference database generated from the FDG-PET scans of normal in-
dividuals. Each scan was compared with the database after controlling
the global activity using Neurostat scaling procedures. Z scores (Z 5
[mean subject−mean database] / SD database) were calculated voxel-
by-voxel at a threshold of P b 0.01 (one-sided) corresponding to
Z N 2.33 for a reduced 18F-FDG uptake in the patient relative to the con-
trol mean. Three-dimensional stereotactic surface projections (3D-SSPs)
of the Z scores were then generated to allow for the visualization of
18F-FDG uptake abnormalities and an examination of the extentand topography of hypometabolism according to a previously described
method [13].
The GABAergic system was examined using PET and [11C]-ﬂumazenil
an antagonistic radioligand that binds to the central benzodiazepine re-
ceptor site of the GABA-A complex. The ﬂumazenil-PET study was
performed with the patient in a resting state with his or her eyes
open under a dim light following the intravenous injection of
5 MBq/kg of [11C]-ﬂumazenil. The accumulation of ﬂumazenil was
recorded for 60 min using dynamic serial scanning. Prior to the PET
scan, MRI (0.3-T MRP/7000 AD; Hitachi, Tokyo, Japan) was performed
with 3-dimensional mode sampling to determine the brain areas for
setting the regions of interest (ROIs). Accordingly, ROIs were placed
on the pons and cerebellum on MRI images then transferred onto the
corresponding PET images, and the semiquantitative ROI/pons ratio
was subsequently calculated by dividing the number of ROIs by the
number of pons based on a previously described method [14]. Two dif-
ferent researchers calculated the ratios three times. Since ﬂumazenil
binding declines with age, we used age-matched controls for compari-
son to eliminate the effects of aging. The values for ﬂumazenil binding
were compared between the patients and normal controls.
3. Results
3.1. Clinical and genetic outcomes
The clinical characteristics of each patient are summarized in
Table 1. Patient 1, who was the mother of Patients 2 and 3, presented
with hemiplegic migraines with progressive cerebellar ataxia lasting
for approximately 20 years. Patients 2 and 3 presented with a several-
year history of progressive cerebellar ataxia accompanied by migraines
with visual and motor aura. A genetic analysis of the CACNA1A gene
showed a homozygous R1347Q mutation (reference sequence:
X99897) in all three patients, and they were diagnosed with FHM1. Pa-
tients 4 and 5 had also experienced cerebellar ataxia for approximately
20 years, although without migraines. These subjects were diagnosed
with SCA6 based on a genetic analysis of the CACNA1A gene, which
showed abnormal CAG expansion at the 3′ end of the CACNA1A gene.
MRI disclosed symmetric cerebellar atrophy of the bilateral hemisphere
and vermis in all patients (Fig. 1); however, no atrophywas noted in the
cerebral cortices or brainstem. The SARA scoreswere in the range of 9 to
10 in all cases.
3.2. PET analysis
The ﬂumazenil-PET analyses of the semi-quantitative ROI/pons ratio
showed a signiﬁcant reduction in ﬂumazenil binding in the cerebellar
vermis and bilateral cerebellar hemisphere in all patients, compared
with that observed in the normal controls (Fig. 2, Table 2). The level of
Fig. 1. T1-weighted MRI images of the patients. All patients showed cerebellar atrophy on axial and sagittal images, whereas cerebral atrophy was not observed.
58 S. Kono et al. / BBA Clinical 2 (2014) 56–61ﬂumazenil binding in the temporal cortex was also decreased in FHM1
Patients 1 and 2.
The metabolic rate of glucose (MRGlc) measured on FDG-PET was
evaluated using a 3D-SSP analysis (Fig. 3). Consequently, all patients ex-
hibited a signiﬁcant decrease in the MRGlc in the bilateral cerebellar
cortex, which presented with mild atrophy on MRI. The MRGlc was
also reduced in the frontotemporal cortex in both the FHM1 and SCA6
patients.
4. Discussion
GABA-A receptor impairment has been demonstrated in ataxic mice
of the rolling mouse Nagoya and tottering mouse strains due to
spontaneous CACNA1A gene mutations. However, no previous studieshave investigated the GABA-A receptor function in human neurological
diseases resulting from CACNA1A gene mutations. The rolling mouse
Nagoya strain carries a point mutation in the voltage-sensing S4 seg-
ment of the third repeat of the α1 subunit encoded by the CACNA1A
gene [15]. In these mice, the GABA receptor function assessed using a
GABA receptor agonist is impaired in the cerebellum, thalamus, pons
and medulla [7]. Meanwhile, tottering mice present with seizures and
involuntarymovements, as well as ataxia, and genetic analyses have re-
vealed a point mutation in the CACNA1A gene encoding the pore-
forming subunit of the P/Q type VGCC [16]. Furthermore, histochemical
analyses in tottering mice have demonstrated a decreased number and
impaired function of GABA-A receptors in the cerebellum and cerebral
cortex, in which aberrant GABA-A receptor subunits are expressed
[8–10]. These ﬁndings led us to hypothesize that the GABA-A receptor
Fig. 2. Superimposed axial PET/MRI images of [11C]-ﬂumazenil in the patients and an age-matched normal control. The colored bar denotes the [11C]-ﬂumazenil standardized uptake value
ratio. The red bar indicates ﬂumazenil binding above the level of the blue bar.
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CACNA1A gene mutations. PET using [11C]-ﬂumazenil, a radioactive
ligand of the GABA-A receptor, is a useful neuroimaging modality for
assessing the in vivo GABA-A receptor function in the living brain. How-
ever, there are no ﬂumazenil-PET studies in patients with hereditary
spinocerebellar ataxia, including SCA6 and FHM. In the present study,
all patients with SCA6 and FHM1 displayed reduced ﬂumazenil binding
in the cerebellum, whereas decreased ﬂumazenil binding in the tempo-
ral cortex was observed only in the FHM1 patients. These PET ﬁndings
suggest that P/Q VGCC mutations contribute to impairment of the
GABA-A receptor function, thus resulting in damage to the cerebellar
GABAergic network, as previously observed in CACNA1Amutant ataxic
mice. Mutant ataxic mice and cases of FHM1 in humans are caused byTable 2
Regional levels of binding potential for [11C]-ﬂumazenil in the patients and controls.
Controls
N = 6
Patient 1
FHM
Right cerebellar hemisphere 2.35 ± 0.20 1.71a
Left cerebellar hemisphere 2.27 ± 0.15 1.71a
Cerebellar vermis 2.60 ± 0.17 1.44a
Right frontal cortex 3.21 ± 0.12 3.23
Left frontal cortex 3.20 ± 0.12 3.20
Right temporal cortex 3.26 ± 0.12 2.93a
Left temporal cortex 3.22 ± 0.12 2.94a
Right parietal cortex 3.34 ± 0.24 3.18
Left parietal cortex 3.30 ± 0.22 3.15
Right occipital cortex 3.10 ± 0.15 2.95
Left occipital cortex 3.11 ± 0.17 2.94
The data are presented as the mean ± SD.
The estimated [11C]-ﬂumazenil binding was calculated as the region of interest (ROI)/pons rati
a Below the range of mean–2 SD for normative data.speciﬁc point mutations in the CACNA1A gene. In addition, biochemical
studies in themice brain show an aberrant GABA-A receptor expression
in the cerebral cortex as well as cerebellum [8,9,17]. The characteristic
ﬁnding of ﬂumazenil-PET studies in FHM1 patients is regional de-
creased GABA-A receptor binding in the temporal cortex. The
cerebrocortical GABA-A receptor impairment observed in FHM1
patients may be associated with pathological mechanisms caused by
point mutations. However, it remains unclear how P/Q VGCCmutations
induce dysfunction of theGABA-A receptor. Biochemical studies of totter-
ing mice show the upregulation of cerebellar L-type voltage-activated
calcium channel m-RNA, which may contribute to the dystonia observed
in these animals [18]. L-type voltage-activated calcium channels regulate
the GABA-A receptor expression in cultured neurons and cerebellarPatient 2
FHM
Patient 3
FHM
Patient 4
SCA6
Patient 5
SCA6
1.34a 1.42a 1.61a 0.98a
1.31a 1.47a 1.65a 1.02a
1.62a 0.97a 1.44a 1.60a
3.07 2.76a 3.26 3.25
3.01 2.68a 3.26 3.25
2.90a 2.68a 3.31 3.33
2.91a 2.67a 3.20 3.46
2.90 2.92 3.24 3.31
3.03 2.90 3.30 3.42
2.83 2.92 3.12 3.16
2.91 2.93 3.14 3.17
o.
Fig. 3.3D-SSP analysis of the cortical [18F]-FDG PETpatterns in thepatients. 3D-SSPmaps and corresponding Z scores showingmetabolic rate of glucose reduction in the patients compared
with that observed in the database of normal subjects are displayed on a color-coded scale ranging from black to red. The Z scores were calculated voxel-by-voxel at a threshold of P b 0.01
corresponding to Z N 2.33.
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GABA-A receptors and L-type voltage-activated calcium channels
may provide clues to elucidating the pathological mechanisms un-
derlying the development of CACNA1A-associated neurological
diseases.
The present study demonstrated clinical characteristics common to
FHM1 and SCA6. The regional patterns of brain hypometabolism obtain-
ed using a voxel-based analysis of FDG binding showed glucose
hypometabolism in the frontotemporal cerebellar cortices as well as
cerebellum in both the SCA6 and FHM1 patients. FDG-PET studies
have been reported previously in SCA1, SCA2, SCA3 and SCA6 patients
[21,22]. Decreased regional glucose metabolism is found in the cerebel-
lum in all SCA patients, while decreased glucosemetabolism is observed
in the brainstem in SCA1, SCA2, SCA3 and the basal nucleus of SCA3 [21,
22]. In SCA6 patients, glucose metabolism is diminished in the frontal
and prefrontal cortices in addition to the cerebellum [22]. A previous
FDG-PET study of FHM1 patients demonstrated hypometabolism in
the frontotemporal cortex and cerebellum [23]. These previous FDG-
PET ﬁndings are consistent with the PET features reported in this study.
Cerebella ataxia is an intriguing neurological sign, noted in two-
thirds of FHM1 patients [4]. Some FHM1 patients develop ataxia with
cerebellar atrophy prior to their ﬁrst migraine attack, while others in
various affected families show only cerebellar ataxia [3,6]. In addition,
some CACNA1A gene point mutations causing FHM1 may be associated
with impairment of the cerebellar system. SCA6 is characterized by
inherited neurodegeneration in the cerebellar system due to amutation
in the CACNA1A gene with expansion of the CAG repeats and may becategorized as a CAG repeat disorder. Recent molecular biological
studies have revealed changes in the P/Q channel activity resulting in
alterations in Ca2+ inﬂux into cells transfected with the expanded
CAG repeats in the CACNA1A gene causing SCA6 andmissensemutations
causing FHM1 [24–26]. These ﬁndings suggest that the pathological
mechanisms of SCA6 have the potential to alter the P/Q VGCC activity,
as well as induce a novel toxic gain of function, independent of the
channel kinetics, as hypothesized for other CAG repeat diseases.5. Conclusions
Neurological disorders associated with CACNA1A gene mutations
have distinct clinical phenotypes. However, recent detailed clinical
reports and molecular pathological studies have identiﬁed patholog-
ical mechanisms common to neurological disorders associated with
CACNA1A gene mutation. The present PET study revealed glucose
hypometabolism and GABA-A receptor dysfunction with novel
clinical characteristics common to FHM1 and SCA6 patients, which
may provide clinical evidence of pathological mechanisms caused
by CACNA1A gene mutations.Financial disclosures
This study was not sponsored by any else. All authors report no
disclosures of ﬁnancial relationships.
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